Nautilus Biotechnology (NAUT) Treasury Shares (2020 - 2021)

Nautilus Biotechnology (NAUT) reported Treasury Shares of $22.2 million for Q1 2021, up 31.65% sequentially from $16.8 million in Q4 2020.

Nautilus Biotechnology (NAUT) Treasury Shares (2020 - 2021) Analysis & Trends

Nautilus Biotechnology (NAUT) has 2 years of Treasury Shares data on file, last reported at $22.2 million in Q1 2021.

For the quarter ending Q1 2021, Treasury Shares changed N/A year-over-year to $22.2 million; the trailing twelve-month figure through Mar 2021 stood at $22.2 million (changed N/A YoY), and the FY2020 full-year result was $16.8 million, changed N/A from the prior year.
Treasury Shares grew to $22.2 million in Q1 2021, from $16.8 million in the prior quarter.
In the past five years, Treasury Shares ranged from a high of $22.2 million in Q2 2020 to a low of $16.8 million in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-21,709.08
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	265,401.92
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	-
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	19.41 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	-
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	5.14 Mn
10	Nautilus Biotechnology	212.11 Mn	116.24 Mn	-	-

Download Data